United States Biotechnology & Medical Research

Rubius Therapeutics Inc (RUBY)

Track

Ticker: RUBY Exchange: NSM
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Rubius Therapeutics Inc. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Appelhans Dannielle
CEO and President
1 sale — total 1,323 USD
Sale 24 Feb 2023
Value US$235,625.80 | Price 261.21 | Shares 37,882
Sale 1 Feb 2023
Value US$4,587,519.62 | Price 211.76 | Shares 80,663
Sale 1 Feb 2023
Value US$969.50 | Price 0.25 | Shares 3,878
Sale 31 Jan 2023
Value US$622.32 | Price 0.24 | Shares 2,593
Sale 31 Jan 2023
Value US$1,744.84 | Price 0.24 | Shares 7,240
Sale 10 Aug 2022
Value US$4,589.60 | Price 0.80 | Shares 5,737
Buy 21 Apr 2022
Value US$43,329.00 | Price 1.44 | Shares 30,000
Sale 1 Feb 2022
Value US$16,544.24 | Price 6.57 | Shares 2,517
Sale 1 Feb 2022
Value US$44,236.29 | Price 6.57 | Shares 6,730
Sale 1 Feb 2022
Value US$17,957.44 | Price 6.57 | Shares 2,732
Buy 19 Mar 2021
Value US$2,030,000.00 | Price 29.00 | Shares 70,000
Buy 19 Mar 2021
Value US$2,030,000.00 | Price 29.00 | Shares 70,000
Buy 19 Mar 2021
Value US$2,030,000.00 | Price 29.00 | Shares 70,000
Planned sale 15 Mar 2021
Value US$505,965.00 | Price 20.24 | Shares 25,000
Planned sale 11 Feb 2021
Value US$398,559.87 | Price 14.93 | Shares 26,704
Planned sale 10 Feb 2021
Value US$109,525.15 | Price 14.79 | Shares 7,404
Planned sale 9 Feb 2021
Value US$31,145.94 | Price 14.83 | Shares 2,100
Planned sale 8 Feb 2021
Value US$1,328,117.20 | Price 14.88 | Shares 89,233
Buy 22 Apr 2020
Value US$104,813.50 | Price 5.52 | Shares 19,000
Buy 14 Apr 2020
Value US$98,693.70 | Price 4.70 | Shares 21,000
Buy 17 Mar 2020
Value US$18,800.00 | Price 3.76 | Shares 5,000
Buy 13 Mar 2020
Value US$20,000.00 | Price 4.00 | Shares 5,000
Buy 13 Mar 2020
Value US$19,100.00 | Price 3.82 | Shares 5,000
Planned sale 16 Dec 2019
Value US$646,900.80 | Price 13.48 | Shares 48,000
Planned sale 14 Oct 2019
Value US$63,874.50 | Price 8.52 | Shares 7,500
Planned sale 17 Sep 2019
Value US$119,309.22 | Price 10.05 | Shares 11,877
Planned sale 16 Sep 2019
Value US$365,897.09 | Price 10.13 | Shares 36,123
Planned sale 15 Jul 2019
Value US$112,048.50 | Price 14.94 | Shares 7,500
Planned sale 20 Jun 2019
Value US$3,385.96 | Price 13.93 | Shares 243
Planned sale 19 Jun 2019
Value US$253,867.56 | Price 13.80 | Shares 18,399
Planned sale 18 Jun 2019
Value US$154,957.78 | Price 14.27 | Shares 10,858
Planned sale 17 Jun 2019
Value US$260,868.50 | Price 14.10 | Shares 18,500
Planned sale 15 Apr 2019
Value US$131,799.00 | Price 17.57 | Shares 7,500
Planned sale 8 Apr 2019
Value US$42,000.00 | Price 20.00 | Shares 2,100
Planned sale 5 Apr 2019
Value US$241,920.00 | Price 20.00 | Shares 12,096
Planned sale 3 Apr 2019
Value US$10,000.00 | Price 20.00 | Shares 500
Planned sale 15 Mar 2019
Value US$760,113.60 | Price 15.84 | Shares 48,000
Planned sale 14 Jan 2019
Value US$109,443.75 | Price 14.59 | Shares 7,500
Buy 20 Jul 2018
Value US$2,300.00 | Price 23.00 | Shares 100
Buy 20 Jul 2018
Value US$57,500.00 | Price 23.00 | Shares 2,500
Buy 20 Jul 2018
Value US$575,000.00 | Price 23.00 | Shares 25,000
Buy 20 Jul 2018
Value US$230,000.00 | Price 23.00 | Shares 10,000
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2023-02-27 2023-02-24 S Sale
3.7
Appelhans Dannielle

CEO and President

Officer
37,882 +36.7%
261.21
US$235,626 		37,882 +36.7% 261.21 US$235,626
2023-02-01 2023-02-01 S Sale
2.4
CAGNONI PABLO J
Non-Executive Director
80,663 +48.5%
211.76
US$4,587,520 		80,663 +48.5% 211.76 US$4,587,520
2023-02-01 2023-02-01 S Sale
3.7
Appelhans Dannielle

CEO and President

Officer
72,139 +32.7%
287.89
US$4,171,071 		72,139 +32.7% 287.89 US$4,171,071
2023-01-31 2023-01-31 S Sale
Turka Laurence A.

Chief Scientific Officer

Officer
2,593 -12.4%
0.24
US$622 		2,593 -12.4% 0.24 US$622
2023-01-31 2023-01-31 S Sale
2.4
CAGNONI PABLO J
Non-Executive Director
7,240 -8.9%
0.24
US$1,745 		7,240 -8.9% 0.24 US$1,745
2022-08-12 2022-08-10 S Sale
3.7
Appelhans Dannielle

Chief Operating Officer

Officer
5,737 -45.9%
0.80
US$4,590 		5,737 -45.9% 0.80 US$4,590
2022-04-22 2022-04-21 B Purchase
2.1
Epstein David R
Non-Executive Director
30,000 +0.6%
1.44
US$43,329 		30,000 +0.6% 1.44 US$43,329
2022-02-01 2022-02-01 S Sale
Turka Laurence A.

Chief Scientific Officer

Officer
2,517 -33.8%
6.57
US$16,544 		2,517 -33.8% 6.57 US$16,544
2022-02-01 2022-02-01 S Sale
2.4
CAGNONI PABLO J

CEO and President

Executive Director
6,730 -15.9%
6.57
US$44,236 		6,730 -15.9% 6.57 US$44,236
2022-02-01 2022-02-01 S Sale
Keson-Brookes Maiken

CLO & Corp. Secretary

Officer
2,732 -33.8%
6.57
US$17,957 		2,732 -33.8% 6.57 US$17,957
2021-03-23 2021-03-19 B Purchase
3.0
Flagship Ventures Fund IV General Partner LLC
Large shareholder
70,000 +2.7%
29.00
US$2,030,000 		70,000 +2.7% 29.00 US$2,030,000
2021-03-23 2021-03-19 B Purchase
3.0
Flagship Ventures Fund IV General Partner LLC
Large shareholder
70,000 +1.2%
29.00
US$2,030,000 		70,000 +1.2% 29.00 US$2,030,000
2021-03-23 2021-03-19 B Purchase
3.0
Flagship Ventures Fund IV General Partner LLC
Large shareholder
70,000 +0.5%
29.00
US$2,030,000 		70,000 +0.5% 29.00 US$2,030,000
2021-03-15 2021-03-15 PlS Planned sale
Keson-Brookes Maiken

CLO & Corp. Secretary

Officer
25,000 -100.0%
20.24
US$505,965 		25,000 -100.0% 20.24 US$505,965
2021-02-16 2021-02-11 PlS Planned sale
2.1
Epstein David R
Non-Executive Director
26,704 -0.6%
14.93
US$398,560 		26,704 -0.6% 14.93 US$398,560
2021-02-10 2021-02-10 PlS Planned sale
2.1
Epstein David R
Non-Executive Director
7,404 -0.2%
14.79
US$109,525 		7,404 -0.2% 14.79 US$109,525
2021-02-10 2021-02-09 PlS Planned sale
2.1
Epstein David R
Non-Executive Director
2,100 -0.0%
14.83
US$31,146 		2,100 -0.0% 14.83 US$31,146
2021-02-10 2021-02-08 PlS Planned sale
2.1
Epstein David R
Non-Executive Director
89,233 -1.9%
14.88
US$1,328,117 		89,233 -1.9% 14.88 US$1,328,117
2020-04-24 2020-04-22 B Purchase
2.3
Coughlin Christina M.

Chief Medical Officer

Officer
19,000 +inf%
5.52
US$104,814 		19,000 +inf% 5.52 US$104,814
2020-04-15 2020-04-14 B Purchase
2.4
CAGNONI PABLO J

CEO and President

Executive Director
21,000 +inf%
4.70
US$98,694 		21,000 +inf% 4.70 US$98,694
2020-03-19 2020-03-17 B Purchase
2.1
Epstein David R
Non-Executive Director
5,000 +0.1%
3.76
US$18,800 		5,000 +0.1% 3.76 US$18,800
2020-03-17 2020-03-13 B Purchase
2.1
Epstein David R
Non-Executive Director
5,000 +0.1%
4.00
US$20,000 		5,000 +0.1% 4.00 US$20,000
2020-03-17 2020-03-13 B Purchase
2.1
Epstein David R
Non-Executive Director
5,000 +0.1%
3.82
US$19,100 		5,000 +0.1% 3.82 US$19,100
2019-12-18 2019-12-16 PlS Planned sale CARPENTER CHRISTOPHER L.

Chief Medical Officer

Officer
48,000 -57.9%
13.48
US$646,901 		48,000 -57.9% 13.48 US$646,901
2019-10-17 2019-10-14 PlS Planned sale
LANGER ROBERT
7,500 -100.0%
8.52
US$63,874 		7,500 -100.0% 8.52 US$63,874
2019-09-18 2019-09-17 PlS Planned sale
CARPENTER CHRISTOPHER L.

Chief Medical Officer
11,877 -25.4%
10.05
US$119,309 		11,877 -25.4% 10.05 US$119,309
2019-09-18 2019-09-16 PlS Planned sale
CARPENTER CHRISTOPHER L.

Chief Medical Officer
36,123 -50.9%
10.13
US$365,897 		36,123 -50.9% 10.13 US$365,897
2019-07-17 2019-07-15 PlS Planned sale
LANGER ROBERT
7,500 -100.0%
14.94
US$112,048 		7,500 -100.0% 14.94 US$112,048
2019-06-24 2019-06-20 PlS Planned sale
CARPENTER CHRISTOPHER L.

Chief Medical Officer
243 -0.7%
13.93
US$3,386 		243 -0.7% 13.93 US$3,386
2019-06-19 2019-06-19 PlS Planned sale
CARPENTER CHRISTOPHER L.

Chief Medical Officer
18,399 -34.6%
13.80
US$253,868 		18,399 -34.6% 13.80 US$253,868
2019-06-19 2019-06-18 PlS Planned sale
CARPENTER CHRISTOPHER L.

Chief Medical Officer
10,858 -23.8%
14.27
US$154,958 		10,858 -23.8% 14.27 US$154,958
2019-06-19 2019-06-17 PlS Planned sale
CARPENTER CHRISTOPHER L.

Chief Medical Officer
18,500 -34.7%
14.10
US$260,868 		18,500 -34.7% 14.10 US$260,868
2019-04-17 2019-04-15 PlS Planned sale
LANGER ROBERT
7,500 -100.0%
17.57
US$131,799 		7,500 -100.0% 17.57 US$131,799
2019-04-10 2019-04-08 PlS Planned sale
NISSEN TORBEN STRAIGHT

President
2,100 -0.1%
20.00
US$42,000 		2,100 -0.1% 20.00 US$42,000
2019-04-05 2019-04-05 PlS Planned sale
NISSEN TORBEN STRAIGHT

President
12,096 -0.7%
20.00
US$241,920 		12,096 -0.7% 20.00 US$241,920
2019-04-05 2019-04-03 PlS Planned sale
NISSEN TORBEN STRAIGHT

President
500 -0.0%
20.00
US$10,000 		500 -0.0% 20.00 US$10,000
2019-03-19 2019-03-15 PlS Planned sale
CARPENTER CHRISTOPHER L.

Chief Medical Officer
48,000 -57.9%
15.84
US$760,114 		48,000 -57.9% 15.84 US$760,114
2019-01-18 2019-01-14 PlS Planned sale
LANGER ROBERT
Non-Executive Director
7,500 -100.0%
14.59
US$109,444 		7,500 -100.0% 14.59 US$109,444
2018-07-23 2018-07-20 B Purchase Pomerantz Roger Non-Executive Director
100 +inf%
23.00
US$2,300 		100 +inf% 23.00 US$2,300
2018-07-23 2018-07-20 B Purchase Sohn Catherine A. Non-Executive Director
2,500 +inf%
23.00
US$57,500 		2,500 +inf% 23.00 US$57,500
2018-07-23 2018-07-20 B Purchase Symonds Jonathan Non-Executive Director
25,000 +inf%
23.00
US$575,000 		25,000 +inf% 23.00 US$575,000
2018-07-23 2018-07-20 B Purchase Cuss Francis M Non-Executive Director
10,000 +inf%
23.00
US$230,000 		10,000 +inf% 23.00 US$230,000
Explore more

More insider trading research around Rubius Therapeutics Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America